Close Menu

NEW YORK (GenomeWeb) – Great Basin said today that it has received 510(k) clearance from the US Food and Drug Administration for its stool bacterial pathogens panel, which "addresses a significant unmet need" for an affordable panel that quickly and accurately diagnoses patients suffering from food-borne gastrointestinal distress.

Great Basin noted that its assay simultaneously detects Salmonella, Shigella, Shiga Toxin-producing E. coli, and Campylobacter — bacterial pathogens that make up nearly 95 percent of all food-borne illnesses in the US.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports that gene therapy approaches are tackling sickle cell disease, but that the cost of treatment is a concern.

The Washington Post reports that a US Senate committee voted this week to approve the nomination of Stephen Hahn to lead the Food and Drug Administration.

One gene regulates hundreds of others to influence facial development, according to New Scientist.

In Nature this week: resources for single-cell analysis, little overlap in the microRNAs used by Salmonella and Shigella to infect host cells, and more.